How Is Chronic Lymphocytic Leukemia Treated?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

In the early stages, chronic lymphocytic leukemia (CLL) may not need treatment and you may be only observed. Many patients may live their normal life span not needing any treatment. Treatment is generally advised in patients with advanced CLL (Rai stage III-IV), if there is bulky disease (lymph nodes, liver spleen), if they have complications of CLL (infections, immune problems), or if they have significant symptoms caused by CLL, such as fatigue, sweats, fever, weight loss, severe skin itching/lesions, or others.

Specific treatment for CLL will be determined by your physician based on:

  • Your age, overall health, and medical history
  • Extent of the disease
  • Stage of the disease
  • Your tolerance for specific medications, procedures, or therapies
  • Expectations for the course of the disease
  • Your opinion or preference
Treatment may include:
  • Chemotherapy
  • Monoclonal antibodies (Rituxan® [rituximab] or Campath® [alemtuzumab]
  • Treatment for complications, such as infection or anemia
  • Bone marrow transplantation
  • Splenectomy - surgery to remove the spleen
  • Radiation therapy
This content was last modified on August 11, 2007 .
Latest Chronic Lymphocytic Leukemia News
Green tea ingredient may fight incurable leukemia

June 4, 2009 — NEW YORK (Reuters Health) - A chemical found in green tea may shrink lymph nodes and reduce white blood cell counts in patients with chronic lymphocytic leukemia (CLL), a new study in the Journal of Clinical Oncology shows.

FDA advisers back Glaxo, Genmab cancer drug

May 29, 2009 — ORLANDO, Florida (Reuters) - A small trial of Arzerra, being developed by GlaxoSmithKline Plc and Genmab for treating chronic lymphocytic leukemia, indicated benefits sufficient for U.S. approval, an advisory committee to regulators said on Friday.

FDA staff questions data on leukemia drug

May 27, 2009 — WASHINGTON (Reuters) - U.S. drug reviewers questioned whether a proposed leukemia drug from GlaxoSmithKline PLC and Genmab provides enough benefit to warrant approval, documents released on Wednesday said.

Select news items provided by Reuters Health